Stem cell injection aims to replace lost brain cells in Parkinson's

NCT ID NCT07166757

Recruiting now Disease control Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a single injection of lab-grown nerve cells made from stem cells to treat early-onset Parkinson's disease. The cells are designed to replace the dopamine-producing neurons that are lost in Parkinson's. The trial has two phases: first, a small safety test in 6-12 people, then a larger blinded study in 81 people comparing the cell injection to a sham procedure. All participants will also take immunosuppressant drugs to prevent rejection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: human allogeneic induced pluripotent stem cell-derived dopaminergic neural progenitor cells
What this could lead to: If successful, this could point toward a cell-replacement therapy that restores dopamine-producing neurons and slows Parkinson's progression.
What could go wrong: This is an early-phase trial (Phase I/II) with a small number of participants, so safety and effectiveness are not yet proven. Participants also need to take immunosuppressants, which carry their own risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY-ONSET PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease young-onset Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE (PD)

Contacts and locations

Locations

Huashan Hospital, Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200040, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.